|
JPH10503179A
(ja)
|
1994-06-24 |
1998-03-24 |
イミュネックス・コーポレーション |
放出制御性ポリペプチド組成物および炎症性腸疾患の治療方法
|
|
IL112834A
(en)
|
1995-03-01 |
2000-12-06 |
Yeda Res & Dev |
Pharmaceutical compositions for controlled release of soluble receptors
|
|
US6020004A
(en)
|
1997-04-17 |
2000-02-01 |
Amgen Inc. |
Biodegradable microparticles for the sustained delivery of therapeutic drugs
|
|
US6541606B2
(en)
|
1997-12-31 |
2003-04-01 |
Altus Biologics Inc. |
Stabilized protein crystals formulations containing them and methods of making them
|
|
US6432449B1
(en)
|
1998-05-18 |
2002-08-13 |
Amgen Inc. |
Biodegradable sustained-release alginate gels
|
|
US6541033B1
(en)
|
1998-06-30 |
2003-04-01 |
Amgen Inc. |
Thermosensitive biodegradable hydrogels for sustained delivery of leptin
|
|
US6451346B1
(en)
|
1998-12-23 |
2002-09-17 |
Amgen Inc |
Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
|
|
US6245740B1
(en)
|
1998-12-23 |
2001-06-12 |
Amgen Inc. |
Polyol:oil suspensions for the sustained release of proteins
|
|
KR20030074693A
(ko)
*
|
2000-12-28 |
2003-09-19 |
알투스 바이올로직스 인코포레이티드 |
전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
|
|
US8821086B2
(en)
*
|
2006-12-22 |
2014-09-02 |
Tennine Corporation |
Method and apparatus for controlled-fracture machining
|
|
WO2008109871A2
(en)
*
|
2007-03-08 |
2008-09-12 |
Irm Llc |
Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof
|
|
EA200901376A1
(ru)
*
|
2007-04-13 |
2010-12-30 |
Новартис Аг |
Молекулы и способы модуляции пропротеинконвертазы субтилизинового/кексинового типа 9(pcsk9)
|
|
US20130072665A1
(en)
*
|
2007-08-23 |
2013-03-21 |
Simon Mark Jackson |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
|
|
JOP20080381B1
(ar)
*
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
|
MX2010011499A
(es)
*
|
2008-04-23 |
2010-11-12 |
Amgen Inc |
Variantes de proproteina neutralizante de convertasa subtilisina kexina de tipo 9 (pcsk9) y sus usos.
|
|
KR100985090B1
(ko)
*
|
2008-05-23 |
2010-10-04 |
한국과학기술연구원 |
크라이센 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법
|
|
WO2011028938A1
(en)
*
|
2009-09-02 |
2011-03-10 |
Alnylam Pharmaceuticals, Inc. |
Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
|
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
|
IN2012DN03824A
(2)
*
|
2009-10-30 |
2015-08-28 |
Merck Sharp & Dohme |
|
|
JO3756B1
(ar)
*
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
|
SG192117A1
(en)
*
|
2011-01-28 |
2013-08-30 |
Sanofi Sa |
Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
|
|
JOP20200043A1
(ar)
*
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
|
US20140004122A1
(en)
*
|
2011-05-10 |
2014-01-02 |
Amgen Inc. |
Methods for treating or preventing cholesterol related disorders
|
|
ITPN20110039A1
(it)
*
|
2011-05-24 |
2012-11-25 |
Keyline S P A |
Blocchetto di presa perfezionato per macchina duplicatrice di chiavi
|
|
AR087305A1
(es)
*
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
EA039663B1
(ru)
*
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
|
US9255154B2
(en)
*
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
|
US20150140005A1
(en)
*
|
2012-05-17 |
2015-05-21 |
Cyon Therapeutics Inc. |
Methods and Uses for Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors
|
|
EP2861624A1
(en)
*
|
2012-06-15 |
2015-04-22 |
F. Hoffmann-La Roche AG |
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
|
|
US20150335615A1
(en)
*
|
2013-01-04 |
2015-11-26 |
Toshihisa Kawai |
Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation
|
|
TWI670279B
(zh)
*
|
2013-03-15 |
2019-09-01 |
Alder Biopharmaceuticals, Inc. |
抗體純化及純度監測
|
|
WO2014150983A2
(en)
*
|
2013-03-15 |
2014-09-25 |
Amgen Inc. |
Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
|
|
US10494442B2
(en)
*
|
2013-06-07 |
2019-12-03 |
Sanofi Biotechnology |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
|
US20150004174A1
(en)
*
|
2013-06-28 |
2015-01-01 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
|
CA2916259C
(en)
*
|
2013-06-28 |
2024-02-20 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
|
ES2914978T3
(es)
*
|
2013-10-11 |
2022-06-20 |
Sanofi Biotechnology |
Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
|
|
CN118105480A
(zh)
*
|
2013-11-12 |
2024-05-31 |
赛诺菲生物技术公司 |
用于与pcsk9抑制剂一起使用的给药方案
|
|
US8883157B1
(en)
*
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9034332B1
(en)
*
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9023359B1
(en)
*
|
2014-07-15 |
2015-05-05 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
EA201691320A1
(ru)
*
|
2014-02-14 |
2016-11-30 |
Ридженерон Фармасьютикалз, Инк. |
Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
|
|
CA2935285A1
(en)
*
|
2014-02-21 |
2015-08-27 |
Medimmune, Llc |
Anti-pcsk9-glp-1 fusions and methods for use
|
|
WO2015140079A1
(en)
*
|
2014-03-17 |
2015-09-24 |
Sanofi |
Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
|
|
AU2015289874A1
(en)
*
|
2014-07-14 |
2017-02-02 |
Amgen Inc. |
Crystalline antibody formulations
|
|
CA2954773C
(en)
*
|
2014-07-14 |
2023-10-03 |
Amgen Inc. |
Crystalline antibody formulations
|
|
KR20230074283A
(ko)
*
|
2014-07-16 |
2023-05-26 |
사노피 바이오테크놀로지 |
이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
|
|
WO2016046684A1
(en)
*
|
2014-09-23 |
2016-03-31 |
Pfizer Inc. |
Treatment with anti-pcsk9 antibodies
|
|
EA039310B1
(ru)
*
|
2015-02-26 |
2022-01-12 |
Санофи Байотекнолоджи |
Способы снижения сердечно-сосудистого риска
|
|
JP7074684B2
(ja)
*
|
2016-04-08 |
2022-05-24 |
アムジエン・インコーポレーテツド |
薬物送達デバイス、製造方法、及び使用方法
|
|
EP3448427A1
(en)
*
|
2016-04-29 |
2019-03-06 |
CureVac AG |
Rna encoding an antibody
|
|
SG10201912565QA
(en)
*
|
2016-09-29 |
2020-02-27 |
Amgen Inc |
Low-viscosity antigen binding proteins and methods of making them
|
|
EP3522918A1
(en)
*
|
2016-10-06 |
2019-08-14 |
Amgen Inc. |
Reduced viscosity protein pharmaceutical formulations
|
|
JOP20190112A1
(ar)
*
|
2016-11-14 |
2019-05-14 |
Amgen Inc |
علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
|
|
US20190031774A1
(en)
*
|
2017-06-09 |
2019-01-31 |
Sanofi Biotechnology |
Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
|
|
MX2020003888A
(es)
*
|
2017-10-18 |
2020-11-06 |
Regenxbio Inc |
Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos.
|
|
EP3833685A4
(en)
*
|
2018-07-08 |
2022-08-17 |
Specifica Inc. |
ANTIBODY LIBRARIES WITH FEATURES FOR MAXIMIZED ANTIBODY DEVELOPMENT
|